Verrica Pharmaceuticals Inc. (VRCA) Q1 2024 Earnings
VRCA·Reported May 13, 2024·Before market open
Verrica Pharmaceuticals Inc. reported Q1 2024 revenue of $3.8M, beat analyst consensus of $2.8M by $1.0M. Diluted EPS came in at $-0.38, beat the $-0.54 consensus by $0.16.
Revenue
$3.8Mbeat by $1.0M
Consensus: $2.8MDiluted EPS
$-0.38beat by $0.16
Consensus: $-0.54
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Verrica Pharmaceuticals Inc.'s Q1 2024 earnings report.
Verrica Pharmaceuticals Inc. (VRCA) reported Q1 2024 earnings on May 13, 2024 before market open.
Verrica Pharmaceuticals Inc. reported revenue of $3.8M and diluted EPS of $-0.38 for Q1 2024.
Revenue beat the consensus estimate of $2.8M by $1.0M. EPS beat the consensus estimate of $-0.54 by $0.16.
You can read the 10-Q periodic report (0000950170-24-058208) directly on SEC EDGAR. The filing index links above go to sec.gov.